CART-19 Immunotherapy in Mantle Cell Lymphoma

Inclusion Criteria: * Male and female with CD19+ relapsed or refractory MCL, and with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to \< 2 year survival) with currently available therapies will be enrolled. * Not eligible or appropriate for conventional allogeneic SCT * Patients who achieve only a partial response to FCR(fludarabine, cyclophosphamide and Rituxan) as initial therapy will be eligible. * Beyond 1st CR (complete remission) with relapsed or persistent disease and not eligible or appropriate for conventional allogeneic or autologous SCT * Disease responding or stable after most recent therapy (chemotherapy, MoAb, etc...) * Relapsed after prior autologous SCT * Residual disease after primary therapy and not eligible for autologous SCT * Relapsed after prior autologous SCT * Beyond 1st CR with relapsed or persistent disease and not eligible or appropriate of conventional allogeneic or autologous SCT * Expected survival \> 12 weeks * Creatinine \< 2.5 mg/dl * ALT(alanine aminotransferase)/AST (aspartate aminotransferase)\< 3x normal * Bilirubin \< 2.0 mg/dl * Any relapse after prior autologous SCT will make patient eligible regardless of other prior therapy * Adequate venous access for apheresis, and no other contraindications for leukapheresis * Voluntary informed consent is given Exclusion Criteria: * • Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion. * Uncontrolled active infection * Active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary * Previously treatment with any gene therapy products * Feasibility assessment during screening demonstrates \< 30% transduction of target lymphocytes, or insufficient expansion (\< 5-fold) in response to CD3/CD137 costimulation * Any uncontrolled active medical disorder that would preclude participation as outlined * HIV infection